keyword
MENU ▼
Read by QxMD icon Read
search

Financial toxicity

keyword
https://www.readbyqxmd.com/read/28724346/biosensing-technologies-for-therapeutic-drug-monitoring
#1
Anna Meneghello, Stefano Tartaggia, Maria Domenica Alvau, Federico Polo, Giuseppe Toffoli
Therapeutic drug monitoring (TDM) is the clinical practice of measuring pharmaceutical drug concentrations in patients' biofluids at designated intervals to allow a close and timely control of their dosage. This practice allows for rapid medical intervention in case of toxicity-related issues and/or adjustment of dosage to better fit the therapeutic demand. Currently, TDM is performed in centralized laboratories employing instruments, such as immunoassay analyzers and mass spectrometers that can be run only by trained personnel...
July 20, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28706513/bacteriocin-antimicrobial-synergy-a-medical-and-food-perspective
#2
REVIEW
Harsh Mathur, Des Field, Mary C Rea, Paul D Cotter, Colin Hill, R Paul Ross
The continuing emergence of multi-drug resistant pathogens has sparked an interest in seeking alternative therapeutic options. Antimicrobial combinatorial therapy is one such avenue. A number of studies have been conducted, involving combinations of bacteriocins with other antimicrobials, to circumvent the development of antimicrobial resistance and/or increase antimicrobial potency. Such bacteriocin-antimicrobial combinations could have tremendous value, in terms of reducing the likelihood of resistance development due to the involvement of two distinct mechanisms of antimicrobial action...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/28691713/targeted-therapies-for-renal-cell-carcinoma
#3
REVIEW
Edwin M Posadas, Suwicha Limvorasak, Robert A Figlin
The management of patients with metastatic renal cell carcinoma (RCC) has changed dramatically over the past few years. Nephrectomy remains an important intervention for localized RCC but systemic therapy is the mainstay of treatment for patients who relapse after surgery or who have metastatic RCC. Before 2005, medical therapies for RCC were limited to cytokine therapies, which are very toxic and benefit only a small percentage of patients. In 2017, therapeutic agents now include kinase and immune checkpoint inhibitors...
August 2017: Nature Reviews. Nephrology
https://www.readbyqxmd.com/read/28685051/personalized-medicine-could-transform-healthcare
#4
Sunil Mathur, Joseph Sutton
Personalized medicine (PM) is about tailoring a treatment as individualized as the disease. The approach relies on identifying genetic, epigenomic, and clinical information that allows the breakthroughs in our understanding of how a person's unique genomic portfolio makes them vulnerable to certain diseases. PM approach is a complete extension of traditional approach (One-Size-Fits-All) to increasing our ability to predict which medical treatments will be safe and effective for individual patient, and which ones will not be, based on the patient's unique genetic profile...
July 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28680956/patient-reported-outcomes-pros-as-part-of-value-based-care-can-shape-therapy-guidelines-impact-on-emerging-targeted-agents-and-immunotherapy-protocols-in-resource-limited-regions
#5
EDITORIAL
Frank E Mott
Patient reported outcomes (PROs) are commonly integrated into clinical trials for new cancer therapies or treatment modalities; however, beyond a cursory review during the registration process for a new drug, these important measures of patient satisfaction and cost-effectiveness are often under-used in daily practice. We cite literature under-scoring the value of PROs not only in clinical trials, but in practical decision making and how such metrics can help guide the oncologist and the patient in choosing the best and most cost-effective therapy for their cancer...
2017: Oncology and Therapy
https://www.readbyqxmd.com/read/28652712/medication-related-issues-associated-with-adherence-to-long-term-tyrosine-kinase-inhibitors-for-controlling-chronic-myeloid-leukemia-a-qualitative-study
#6
Bee Kim Tan, Seng Beng Tan, Li-Chia Chen, Kian Meng Chang, Siew Siang Chua, Sharmini Balashanker, Habiba Nazeera Begum Kamarul Jaman, Syed Carlo Edmund, Ping Chong Bee
PURPOSE: Poor adherence to tyrosine kinase inhibitors (TKIs) could compromise the control of chronic myeloid leukemia (CML) and contributes to poorer survival. Little is known about how medication-related issues affect CML patients' adherence to TKI therapy in Malaysia. This qualitative study aimed to explore these issues. PATIENTS AND METHODS: Individual face-to-face, semistructured interviews were conducted at the hematology outpatient clinics of two medical centers in Malaysia from August 2015 to January 2016...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28650592/om-lv20-a-novel-peptide-from-odorous-frog-skin-accelerates-wound-healing-in-vitro-and-in-vivo
#7
Xiaojie Li, Ying Wang, Zhirong Zou, Meifeng Yang, Chunyun Wu, Yunshan Su, Jing Tang, Xinwang Yang
The healing of chronic wounds remains a considerable challenge in clinical trials and imposes severe financial and physiological burdens on patients. Many works are being tried to find ideal clinical promoting-wound-healing biomaterials. Small bioactive peptides with low cost and easy production, store and transfer become excellent candidates. Here, we identified a novel peptide (named OM-LV20) from skin secretions of odorous frog Odorrana margaretae. The peptide had an amino acid sequence of 'LVGKLLKGAVGDVCGLLPIC', contained an intramolecular disulfide bridge at the C-terminus, and was produced by posttranslational processing of a 71-residue prepropeptide...
June 26, 2017: Chemical Biology & Drug Design
https://www.readbyqxmd.com/read/28648732/-adoptive-transfer-of-t-lymphocytes
#8
H Vié, B Clémenceau
Within a few years, the success of treatments based on the use of T-cells armed with a chimeric T-receptor for the CD19 molecule (CAR-T CD19) has revolutionized the perception of adoptive transfer approaches. The levels of responses observed in acute leukemias, of the order of 70-90 % are indeed unprecedented. The medical and financial enthusiasm aroused by these results has led to the current situation where more than 300 clinical trials are under way, against some thirty different antigens. This enthusiasm, well justified by the first successes, must however be tempered by the difficulties associated with the use of these cells...
June 22, 2017: Transfusion Clinique et Biologique: Journal de la Société Française de Transfusion Sanguine
https://www.readbyqxmd.com/read/28641097/long-term-complications-after-hematopoietic-cell-transplantation
#9
REVIEW
Navneet S Majhail
The prevalence of autologous and allogeneic hematopoietic cell transplantation (HCT) survivors continues to increase. Among patients whose disease remains in remission for the first 2-5years after transplantation, it is estimated that approximately 80-90% will be alive over the subsequent 10years. However, the relative mortality rates of such patients continue to remain higher than those of their general population peers, with late complications contributing to significant long-term morbidity and mortality...
June 13, 2017: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28622195/financial-toxicity-among-patients-with-cancer-where-to-from-here
#10
Louisa G Gordon, Raymond Javan Chan
No abstract text is available yet for this article.
July 2017: Cancer Nursing
https://www.readbyqxmd.com/read/28597105/role-of-aspirin-in-breast-cancer-survival
#11
REVIEW
Wendy Y Chen, Michelle D Holmes
Chemotherapy and hormonal therapy have significantly decreased breast cancer mortality, although with considerable side effects and financial costs. In the USA, over three million women are living after a breast cancer diagnosis and are eager for new treatments that are low in toxicity and cost. Multiple observational studies have reported improved breast cancer survival with regular aspirin use. Furthermore, pooled data from five large randomized trials of aspirin for cardiovascular disease showed that subjects on aspirin had decreased risk of cancer mortality and decreased risk of metastatic cancer...
July 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28590794/transforming-practices-through-the-oncology-care-model-financial-toxicity-and-counseling
#12
Daniel E Sherman
No abstract text is available yet for this article.
June 7, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28587021/patient-reported-distress-and-financial-toxicity-in-patients-receiving-thoracic-radiation-therapy
#13
G Strong, L Hintenlang, N Jagadesh, D Whitaker, Y Habboush, S J Buskirk, J L Peterson, K S Tzou, S Ko, L A Vallow, B C May, R C Miller
No abstract text is available yet for this article.
May 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28561659/how-should-we-intervene-on-the-financial-toxicity-of-cancer-care-one-shot-four-perspectives
#14
S Yousuf Zafar, Lee N Newcomer, Justin McCarthy, Shelley Fuld Nasso, Leonard B Saltz
The median price of a month of chemotherapy has increased by an order of magnitude during the past 20 years, far exceeding inflation over the same period. Along with rising prices, increases in cost sharing have forced patients to directly shoulder a greater portion of those costs, resulting in undue financial burden and, in some cases, cost-related nonadherence to treatment. What can we do to intervene on treatment-related financial toxicity of patients? No one party can single-handedly solve the problem, and the solution must be multifaceted and creative...
2017: American Society of Clinical Oncology Educational Book
https://www.readbyqxmd.com/read/28559763/financial-toxicity-of-cancer-drugs-possible-remedies-from-an-ethical-perspective
#15
Georg Marckmann, Jürgen In der Schmitten
Spiraling costs of cancer treatments have become a major concern for the payers in the health care system and for individual patients suffering from the cancer drugs' financial toxicity. This article discusses possible solutions from an ethical perspective. First, it gives some orientation about what constitutes a fair price for innovative anticancer agents. While a definitive answer remains difficult, there are good reasons to enter into price negotiations with the pharmaceutical companies to align the price with the R&D costs and the added value of the product...
May 2017: Breast Care
https://www.readbyqxmd.com/read/28559762/accurate-measurement-of-financial-toxicity-is-a-prerequisite-to-finding-a-remedy
#16
EDITORIAL
Adam Martin, Peter S Hall
No abstract text is available yet for this article.
May 2017: Breast Care
https://www.readbyqxmd.com/read/28469333/treatment-challenges-and-survival-analysis-of-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-in-real-world
#17
Praveen Adusumilli, Meher Lakshmi Konatam, Sadashivudu Gundeti, Stalin Bala, Lakshmi Srinivas Maddali
CONTEXT: Advent of trastuzumab has brought tremendous changes in the survival of human epidermal growth factor receptor 2 (Her2)-positive breast cancer patients. Despite the availability of the drug, it is still out of reach for many patients. There is very limited real world data regarding treatment challenges and survival analysis of these patients. AIMS AND OBJECTIVES: Primary objective is disease-free survival (DFS) and secondary objective is overall survival (OS) and toxicity profile...
January 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28435252/polyphenol-nanoformulations-for-cancer-therapy-experimental-evidence-and-clinical-perspective
#18
REVIEW
Yasamin Davatgaran-Taghipour, Salar Masoomzadeh, Mohammad Hosein Farzaei, Roodabeh Bahramsoltani, Zahra Karimi-Soureh, Roja Rahimi, Mohammad Abdollahi
Cancer is defined as the abnormal cell growth that can cause life-threatening malignancies with high financial costs for patients as well as the health care system. Natural polyphenols have long been used for the prevention and treatment of several disorders due to their antioxidant, anti-inflammatory, cytotoxic, antineoplastic, and immunomodulatory effects discussed in the literature; thus, these phytochemicals are potentially able to act as chemopreventive and chemotherapeutic agents in different types of cancer...
2017: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/28432099/acute-hepatopancreatic-necrosis-disease-causing-vibrio-parahaemolyticus-strains-maintain-an-antibacterial-type-vi-secretion-system-with-versatile-effector-repertoires
#19
Peng Li, Lisa N Kinch, Ann Ray, Ankur B Dalia, Qian Cong, Linda M Nunan, Andrew Camilli, Nick V Grishin, Dor Salomon, Kim Orth
Acute hepatopancreatic necrosis disease (AHPND) is a newly emerging shrimp disease that has severely damaged the global shrimp industry. AHPND is caused by toxic strains of Vibrio parahaemolyticus that have acquired a "selfish plasmid" encoding the deadly binary toxins PirA(vp)/PirB(vp) To better understand the repertoire of virulence factors in AHPND-causing V. parahaemolyticus, we conducted a comparative analysis using the genome sequences of the clinical strain RIMD2210633 and of environmental non-AHPND and toxic AHPND isolates of V...
July 1, 2017: Applied and Environmental Microbiology
https://www.readbyqxmd.com/read/28428282/whither-radioimmunotherapy-to-be-or-not-to-be
#20
Damian J Green, Oliver W Press
Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive results in preclinical experiments and in clinical trials conducted in radiosensitive malignancies, particularly B-cell lymphomas. Two "first-generation," directly radiolabeled anti-CD20 antibodies, (131)iodine-tositumomab and (90)yttrium-ibritumomab tiuxetan, were FDA-approved more than a decade ago but have been little utilized because of a variety of medical, financial, and logistic obstacles. Newer technologies employing multistep "pretargeting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therapeutic efficacy of radioimmunotherapy and diminished its toxicities...
May 1, 2017: Cancer Research
keyword
keyword
112948
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"